Plethysmograph Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Plethysmograph Market Trends and Insights

Rising Burden of COPD, Asthma, and Other Complex Respiratory Disorders

The plethysmograph market has a strong demand floor because COPD and asthma already affect an estimated 650 million children and adults worldwide, which keeps diagnostic needs broad across both mature and developing care systems. The same medical literature indicates that the prevalence of these respiratory conditions is expected to more than double by 2050, which means care systems are preparing for a larger future pool of patients who require deeper lung assessment than routine spirometry provides.^{[1]Davies Adeloye et al., “Addressing the Global Challenges of COPD and Asthma,” European Respiratory Journal, doi.org} The economic burden adds urgency, with the CHEST Journal estimating that direct global COPD costs were USD 3.9 trillion in 2025 and will rise to USD 24.4 trillion by 2050, making accurate diagnosis a practical cost-control tool rather than an optional add-on.^{[2]Elroy Boers et al., “Forecasting the Global Economic and Health Burden of COPD From 2025 Through 2050,” CHEST Journal, doi.org} The plethysmograph market benefits because body-based lung-volume testing detects trapped gas behind obstructions and structural damage that gas dilution techniques can miss in patients who often drive the highest treatment burden. As a result, the plethysmograph market is expanding on the back of a disease pattern that is clinically complex, financially costly, and unlikely to ease over the forecast period.

Growing Demand for Gold-Standard Lung Volume Measurement in Pulmonary Labs

The plethysmograph market is also being supported by the continued preference for body plethysmography when clinicians need a noninvasive reference method for lung-volume measurement in difficult respiratory cases. A 2025 peer-reviewed analysis highlighted its higher sensitivity for restrictive ventilatory defects associated with long COVID, which broadens its relevance beyond long-established COPD and asthma testing pathways.^{[3]Medtech Journal Ukraine, “The Role of Body Plethysmography in Modern Respiratory Diagnostics,” Medtech MPHU, medtech.mphu.edu.ua} The same quality advantage is carried into drug development, because clinical programs increasingly need outcome measures that capture total lung capacity and airway resistance with greater precision than simpler spirometric markers. The plethysmograph market, therefore, gains an additional buyer group in contract research organizations, academic hospitals, and phase II and phase III trial sites that need calibrated systems for protocol consistency. 

Wider Adoption of Portable and Point-of-Care Respiratory Diagnostics

The plethysmograph market is gradually moving beyond the traditional full-booth laboratory model as compact platforms reduce the space burden that historically limited placement to purpose-built pulmonary labs. Portable system design matters because it opens a path into community clinics, outpatient specialty centers, and occupational settings that could not justify large fixed installations under older workflow assumptions. Company material from ndd and SCHILLER shows how calibration-reduced and ultrasonic flow technologies are being positioned around simpler setup, lower maintenance demands, and faster readiness for testing. That operating model improves the appeal of the plethysmograph market in decentralized care because staff can spend less time on warm-up, calibration, and repeated quality checks, which directly affects throughput and total ownership cost. The recent launch of nddHub further shows how vendors are trying to extend value from device sales into fleet oversight, performance monitoring, and network-level quality control across multiple sites. As these digital and portable features spread, the plethysmograph market becomes easier to scale in outpatient settings without losing the quality discipline expected in formal respiratory testing.

Expanding Use in Occupational and Pre-Employment Respiratory Screening

The plethysmograph market is finding another source of demand in occupational health, where employers and clinical evaluators need stronger baseline respiratory documentation before workers enter exposure-heavy roles. A 2026 perspective in the American Journal of Respiratory and Critical Care Medicine emphasized the evidentiary role of spirometry in work ability and impairment assessment, which supports the broader move toward more defensible baseline lung-function records. The plethysmograph market benefits because these programs are shifting from periodic reactive monitoring toward baseline testing that can stand up to later clinical and legal review. This use case is especially relevant in regions with large industrial workforces and exposure concerns, where respiratory assessment is increasingly tied to risk management rather than only to treatment decisions. The result is a broader installed-base opportunity for the plethysmograph market in pre-employment and occupational medical centers that need more robust pulmonary documentation.

High Capital Cost and Facility Footprint of Body Plethysmograph Systems

The plethysmograph market still faces a meaningful adoption barrier because traditional body systems remain expensive capital purchases for small hospitals, private practices, and lower-resource diagnostic networks. PulmOne’s 2025 ownership-cost analysis shows that the burden extends beyond acquisition and includes HVAC needs, calibration service contracts, and per-test workflow demands that can limit daily volume. These economics become harder to justify when utilization is uneven, since providers must recover depreciation and service costs through testing volumes that are often lower outside major academic centers. The plethysmograph market, therefore, sees slower penetration in sites that cannot rely on high-volume pulmonary workups or broad payer support, even when clinicians recognize the diagnostic value of full lung-volume testing. Compact designs can ease part of this problem, but the plethysmograph market remains exposed to a capital equation that still favors larger institutions.

Limited Skilled Technicians for Correct Test Execution and Interpretation

The plethysmograph market is also held back by an operator skills gap, because reliable testing depends on correct patient coaching, repeatability checks, and accurate interpretation rather than on hardware alone. This issue matters across the plethysmograph market because poor technique reduces throughput, increases repeat tests, and weakens confidence in results, especially in centers that do not have credentialed respiratory specialists on site. Infection control and cleaning add another layer of friction in shared labs, since enclosed testing environments and reusable components require disciplined room turnover and device sanitation protocols. Those practical steps can slow appointment flow and make smaller sites question whether they can support enough daily volume to justify a full system. Until staffing depth and workflow consistency improve more broadly, the plethysmograph market will continue to grow below its clinical potential in several under-resourced settings.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Body Plethysmographs Hold the Core Base While Air Systems Grow Faster

Body plethysmographs captured 34.41% of the plethysmograph market size in 2025, which reflects their established role in measuring total lung capacity, residual volume, and airway resistance in formal respiratory testing environments. A 2025 peer-reviewed review also reinforced the clinical position of plethysmography-derived total lung capacity in COPD evaluation by showing a strong correlation with residual volume and hyperinflation severity. This keeps the plethysmograph market anchored in high-acuity lung assessment, where the accuracy of lung-volume measurement matters more than the convenience of lower-cost substitutes. It also supports durable demand from hospital laboratories that need reference-grade results for diagnosis, staging, and follow-up.

Air plethysmographs are forecasted to be the fastest-growing product type at 7.73% CAGR from 2026 to 2031, which shows how the plethysmograph market is broadening beyond its traditional respiratory core. Photo plethysmographs and impedance plethysmographs also retain meaningful roles, with photoplethysmography expanding through monitoring applications and impedance-based systems showing clinical utility in lower-extremity artery disease assessment. Venous occlusion and research-oriented systems remain smaller, but they still serve trial work and specialized physiology testing where precise blood-flow response data are needed. 

By Application: Pulmonary Function Testing Keeps the Largest Share, While Cardiovascular Use Expands

Pulmonary function testing accounted for 38.52% of the plethysmograph market size in 2025, which shows that respiratory diagnostics still form the core demand base for the category. The plethysmograph market continues to benefit from the fact that accredited respiratory laboratories rely on consistent protocols and repeatable quality standards, which makes technology substitution slower in this application than in some simpler testing categories. As long as respiratory disease burden remains high, pulmonary function testing should remain the foundation of the plethysmograph market.

Cardiovascular disease diagnosis is expected to be the fastest-growing application at 7.14% CAGR through 2031, reflecting a wider clinical appreciation for plethysmography in peripheral arterial disease, venous insufficiency, and related hemodynamic assessment. A 2025 multicenter study showed that combining ankle-brachial index with pulse volume wave parameters improved peripheral arterial disease diagnostic sensitivity to 85.4%, compared with 67% for a single-parameter ABI approach. The plethysmograph market is therefore gaining from a broader buyer universe that now includes cardiology and vascular medicine alongside pulmonology. 

By End-User: Hospitals Lead the Installed Base While Pulmonary Care Centers Gain Speed

Hospitals held 42.11% of the plethysmograph market share in 2025, which reflects the capital intensity of the equipment and the long-standing concentration of advanced testing inside academic and teaching centers. The hospital setting remains important because it offers the physical space, staff depth, and patient mix needed to support full-scale plethysmography with acceptable utilization levels. Diagnostic laboratories remain a stable secondary group in the plethysmograph market because they can aggregate referral volumes and support dedicated respiratory workflows without carrying the full overhead structure of inpatient facilities. 

Pulmonary care centers are forecasted to grow at 8.04% CAGR through 2031, showing how the plethysmograph market is gradually following respiratory care into lower-cost outpatient settings. The plethysmograph market is better suited to this channel now because compact systems and remote monitoring tools make distributed deployment more practical than it was under older full-lab models. Other end-users, including pharmaceutical companies and contract research organizations, are also adding demand where respiratory endpoints require controlled and repeatable lung-function data.

Geography Analysis

North America accounted for 45.31% of the plethysmograph market share in 2025, which made it the largest regional contributor to revenue. The region benefits from dense pulmonology laboratory networks, broader use of established pulmonary billing codes, and a care environment that supports more formal respiratory workups than many other markets. The United States remains the main country anchor because large hospitals and academic centers can support both the capital cost and the staffing requirements associated with advanced lung-function testing. The plethysmograph market also holds up well in North America because occupational assessment, specialty pulmonary care, and research activity all reinforce the installed base rather than depending on one demand channel alone.

Europe remained the second-largest regional market in 2025 and continued to show steady demand from established respiratory testing systems. The plethysmograph market in Europe benefits from structured clinical practice, strong specialist referral pathways, and a long-standing role for lung-volume measurement in COPD and restrictive disease workups. A 2025 peer-reviewed analysis also linked body plethysmography to higher sensitivity in restrictive ventilatory defects associated with long COVID, which supports continued clinical use across hospital respiratory services. At the same time, the full enforcement environment around the EU Medical Device Regulation in 2024 has raised compliance demands related to clinical evidence, quality systems, and post-market oversight. That regulatory pressure favors better-resourced suppliers in the plethysmograph market and makes it harder for smaller vendors to sustain participation without heavier investment in compliance.

Asia-Pacific is projected to record the fastest plethysmograph market growth at 9.11% CAGR through 2031. The plethysmograph market in the region is being lifted by healthcare infrastructure expansion, a large burden of chronic respiratory disease, and a rising need for specialist diagnostics outside the most established urban hospitals. Outside Asia-Pacific, demand in the Middle East and Africa remains concentrated in the GCC and select academic centers, while South America is led by private hospital demand and occupational health use, where capital budgets allow. The plethysmograph market, therefore, shows a clear regional split, with mature demand concentrated in North America and Europe, and faster incremental expansion coming from Asia-Pacific and selected emerging healthcare systems.